Don’t take on your condition alone

Target-Icon

LYNPARZA is a type of targeted therapy called a PARP inhibitor. It’s used to treat adults who have an inherited BRCA mutation (also known as gBRCA or germline BRCA) and HER2-negative metastatic breast cancer that has been treated with chemotherapy, and if HR-positive, treated with hormonal therapy.

Damage-Icon

Cancer can begin when cells grow out of control. Due to this growth, cancer cells have a higher risk of DNA damage.

Repair-Icon

To help repair this damage and survive, the cancer cells rely on several different methods, including one that involves the PARP enzyme.

Destroyed-Icon

By helping to stop PARP, LYNPARZA can limit a cancer cell’s ability to repair DNA damage. And that can lead to cancer cell death. LYNPARZA may also impact other cells and tissues in the body.

Learn more about how PARP inhibitors work in breast cancer.

HER2=human epidermal growth factor receptor 2; HR=hormone receptor; PARP=poly (ADP-ribose) polymerase.

See the study results for LYNPARZA

The purpose of this study was to see how safe and effective LYNPARZA is as a treatment for patients with an inherited BRCA mutation and HER2-negative metastatic breast cancer who were treated with chemotherapy, and if HR-positive, treated with hormonal therapy.

There are a few ways for researchers to see if LYNPARZA is working. In this study, health care providers measured how long LYNPARZA delayed disease progression, which means they measured how long women lived without their cancer getting worse.

STUDY DESIGN

LYNPARZA was studied in 302 patients with an inherited BRCA mutation and HER2-negative metastatic breast cancer who were treated with chemotherapy. Patients were either HR-positive (50%) or triple negative (50%). 205 patients were given 2 LYNPARZA tablets (150 mg each) 2 times a day, and 97 patients were given certain chemotherapies chosen by their health care provider.

RESULTS

Delayed progression by 7 months

The primary results of the study showed that LYNPARZA delayed disease progression by a median of 7 months compared with 4.2 months for patients who were given certain chemotherapies. This means that LYNPARZA slowed the progression of cancer 60% longer than certain chemotherapies.

LYNPARZA reduced the risk of cancer growing, spreading, or getting worse by 42% compared with certain chemotherapies.

LYNPARZA was more than 2 times as likely to shrink tumors compared with certain chemotherapies (52% vs 23%).*

*This data is based on patients with tumors that responded to LYNPARZA (167 patients) or chemotherapy (66 patients).

SAFETY

The most common adverse reactions included anemia, a low count of white blood cells, nausea, vomiting, diarrhea, respiratory tract infection, tiredness or weakness, and headache. Other adverse reactions included cough, loss of appetite, low number of blood platelets, changes in how food tastes, a low count of white blood cells, dizziness, indigestion, mouth sores, pain or discomfort in the stomach area, rash, increase in creatinine, and eczema. Because of an adverse reaction, 35% of patients interrupted treatment with LYNPARZA, and 28% interrupted treatment with chemotherapy; 25% of patients had their LYNPARZA doses reduced, and 31% had their chemotherapy doses reduced; and 5% of patients stopped treatment with LYNPARZA, and 8% stopped treatment with chemotherapy.
These are not the only side effects associated with LYNPARZA.

Ask your health care provider what LYNPARZA may do for you.

Important Safety Information

WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have a certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your health care provider will perform a test to make sure that LYNPARZA is right for you.

It is not known if LYNPARZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your health care provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include: weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

Your health care provider will do blood tests to check your blood cell counts:

  • before treatment with LYNPARZA
  • every month during treatment with LYNPARZA
  • weekly if you have low blood cell counts that last a long time. Your health care provider may stop treatment with LYNPARZA until your blood cell counts improve.

Lung problems (pneumonitis). Tell your health care provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your health care provider may do a chest x-ray if you have any of these symptoms. Your health care provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

Before taking LYNPARZA, tell your health care provider about all of your medical conditions, including if you:

  • have lung or breathing problems
  • have kidney problems
  • are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage).
    • If you are able to become pregnant, your health care provider may do a pregnancy test before you start treatment with LYNPARZA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your health care provider about birth control methods that may be right for you.
    • Males with female partners who are pregnant or able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA.
    • Do not donate sperm during treatment with LYNPARZA and for 3 months after your final dose.
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your health care provider about the best way to feed your baby during this time.

Tell your health care provider right away if you become pregnant.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

How should I take LYNPARZA?

  • Take LYNPARZA tablets exactly as your health care provider tells you
  • Your health care provider may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects
  • Do not take more than 4 LYNPARZA tablets in 1 day
  • Take LYNPARZA by mouth 2 times a day
  • Each dose should be taken about 12 hours apart
  • Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
  • Take LYNPARZA with or without food
  • If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time
  • Do not take an extra dose to make up for a missed dose
  • If you take too much LYNPARZA, call your health care provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?

Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:

  • nausea or vomiting. Tell your health care provider if you get nausea or vomiting. Your health care provider may prescribe medicines to treat these symptoms
  • low number of red or white blood cells
  • tiredness or weakness
  • sore throat or runny nose
  • diarrhea
  • joint, muscle, and back pain
  • headache
  • constipation
  • changes in the way food tastes
  • loss of appetite
  • mouth sores
  • respiratory infections
  • changes in kidney function blood test
  • low number of platelets
  • indigestion or heartburn

These are not all the possible side effects of LYNPARZA. Call your health care provider for medical advice about side effects.

You may report side effects related to AstraZeneca products by clicking here.

Please see complete Prescribing Information, including Patient Information (Medication Guide).